Accueil>>Signaling Pathways>> Ubiquitination/ Proteasome>> Proteasome>>LMP7-IN-1

LMP7-IN-1

Catalog No.GC34649

LMP7-IN-1 est un inhibiteur de la sous-unité d'immunoprotéasome LMP7 (β5i) biodisponible par voie orale, puissant, réversible et hautement sélectif. LMP7-IN-1 exerce une puissance biochimique (IC50 = 3,6 nM) et cellulaire (IC50 = 3,4 nM) élevée contre la sous-unité LMP7. LMP7-IN-1 montre une forte efficacité antitumorale dans des modèles de xénogreffes de myélome multiple. LMP7-IN-1 conduit À une suppression significative et prolongée de l'activité LMP7 tumorale et du renouvellement des protéines ubiquitinées et À l'induction de l'apoptose dans les cellules de myélome multiple.

Products are for research use only. Not for human use. We do not sell to patients.

LMP7-IN-1 Chemical Structure

Cas No.: 2285330-15-4

Taille Prix Stock Qté
5mg
454,00 $US
En stock
10mg
732,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LMP7-IN-1 is an inhibitor of immunoproteasome (LMP7), may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer[1]. LMP7[1]

LMP7-IN-1 (Example 2) is an inhibitor of immunoproteasome (LMP7), may used in the research of inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer[1].

[1]. Markus Klein, et al. Boronic acid derivatives. WO2019038250A1.

Avis

Review for LMP7-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LMP7-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.